University Hospital Puerta de Hierro Majadahonda
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rodriguez, Eva
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
Cruz, Ana Fernández
HOLA, NCT06185452: Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

Active, not recruiting
4
110
Europe
Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration, Administration of LA CAB+RPV in the hospital, Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration, Administration of LA CAB+RPV out of hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV-1 Infection
03/25
03/25
MARIO, NCT05178862 / 2022-000648-32: A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Suspended
3
220
Europe, Canada, US, RoW
SCY-078, Ibrexafungerp, Fluconazole, Diflucan, Echinocandin, Caspofungin, Micafungin, Anidulafungin
Scynexis, Inc., SCYNEXIS, Inc.
Candidiasis, Invasive, Candidemia
06/24
08/24
NCT06643897: Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Long- Acting Combination Cabotegravir+Rilpivirina.

Completed
N/A
13
Europe
Qualitative Interview
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
HIV-1-infection
10/24
10/24
PETIFI, NCT05688592: Usefulness of PET-CT for Invasive Fungal Infection

Recruiting
N/A
224
Europe
PET-CT, Before-and-after study
Puerta de Hierro University Hospital, Gilead Sciences
Invasive Fungal Infections
10/24
12/24

Download Options